Bailliere's clinical endocrinology and metabolism最新文献_第3页

9Experimental studies on lignans and cancer 木脂素与癌症的实验研究

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-12-01 DOI: 10.1016/S0950-351X(98)80011-6

BSc, MSc, PhD Lilian U. Thompson (Professor)

引用次数: 117

Phytoestrogens and the menopause. 植物雌激素和更年期。

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-12-01 DOI: 10.3109/13697139809085559

R. Mackey, J. Eden

引用次数: 43

Androgen therapy in chronic renal failure 慢性肾衰竭的雄激素治疗

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80248-6

MB Bs, PhD, FRACP David J. Handelsman (Director), MB BS, FRACP Peter Y. Liu (Research Fellow)

引用次数: 32

Potential adverse effects of long-term testosterone therapy 长期睾酮治疗的潜在副作用

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80305-4

Dr. Med Claus Rolf, FRCP Eberhard Nieschlag

{"title":"Potential adverse effects of long-term testosterone therapy","authors":"Dr. Med Claus Rolf, FRCP Eberhard Nieschlag","doi":"10.1016/S0950-351X(98)80305-4","DOIUrl":"10.1016/S0950-351X(98)80305-4","url":null,"abstract":"<div><p>Natural testosterone and its esters, even when applied in supraphysiological doses, rarely produce side-effects. Via a negative feedback mechanism, exogenous testosterone suppresses the production of lutenizing hormone and follicle stimulating hormone, and leads to reduced testicular sperm production and, consequently, reduced testicular volume. The main concerns for the potential adverse effects of testosterone treatment are the prostate and the cardiovascular system. Androgens play a permissive role in the development of prostate cancer and benign prostate hyperplasia; however, there are no data to indicate that testosterone administration can lead to the progression of pre-clinical or clinical prostate cancer. Whether the effects of testosterone treatment on lipid metabolism are clinically relevant is as yet undetermined. The effects of testosterone on behaviour, especially on aggression, have not been firmly established. Some androgen effects, such as virilization and coarsening of the voice, considered normal in adult men are inappropriate in women and children.</p></div>","PeriodicalId":77027,"journal":{"name":"Bailliere's clinical endocrinology and metabolism","volume":"12 3","pages":"Pages 521-534"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-351X(98)80305-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21201393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 69

Index 指数

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80324-8

引用次数: 0

Rationale for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease 合成代谢疗法促进慢性阻塞性肺疾病患者康复的基本原理

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80134-1

PhD, MD Richard Casaburi (Professor of Medicine)

{"title":"Rationale for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease","authors":"PhD, MD Richard Casaburi (Professor of Medicine)","doi":"10.1016/S0950-351X(98)80134-1","DOIUrl":"10.1016/S0950-351X(98)80134-1","url":null,"abstract":"<div><p>Chronic obstructive pulmonary disease (COPD) afflicts millions of people and is severely disabling. Exercise intolerance is usually the chief complaint. There are few effective therapies. Pulmonary rehabilitation seeks to return the patient to the highest possible level of function but cannot reverse the underlying pulmonary abnormalities. Several lines of evidence have recently pointed to abnormalities of the muscles of ambulation as a remediable source of exercise intolerance in COPD. Possible mechanisms of the muscle abnormalities include deconditioning, malnutrition, low levels of anabolic hormones and, perhaps, a specific myopathy. To date, most reports of attempts to reverse muscle dysfunction in COPD have focused on exercise training. However, abnormalities in the level of circulating anabolic hormones have recently been described, suggesting that anabolic hormone supplementation may be rational therapy for these patients. Accumulating evidence that anabolic steroids increase muscle mass and improve strength in older men is encouraging trials of anabolic steroids in men with COPD.</p></div>","PeriodicalId":77027,"journal":{"name":"Bailliere's clinical endocrinology and metabolism","volume":"12 3","pages":"Pages 407-418"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-351X(98)80134-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21201498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 41

Previous issues 以前的问题

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80020-7

引用次数: 0

Androgens and abdominal obesity 雄激素和腹部肥胖

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80191-2

MD, PhD Per Mrin (Associate Professor and Senior Physician), MD, PhD Stefan Arver (Director and Associate Professor)

{"title":"Androgens and abdominal obesity","authors":"MD, PhD Per Mrin (Associate Professor and Senior Physician), MD, PhD Stefan Arver (Director and Associate Professor)","doi":"10.1016/S0950-351X(98)80191-2","DOIUrl":"10.1016/S0950-351X(98)80191-2","url":null,"abstract":"<div><p>Central or visceral obesity is recognized as a main risk factor for cardiovascular disease and type 2 diabetes mellitus. The co-existence of visceral obesity, increased blood lipid levels, hypertension and impaired glucose tolerance defines the metabolic syndrome that today is widely recognized as one of the prime factors behind cardiovascular morbidity and mortality.</p><p>Endocrine disorders such as insulinoma, hypothyroidism and hypercortisolism are known to cause obesity. However, it is only hypercortisolism that is associated with increased abdominal fat accumulation.</p><p>Recently, new findings have shed light on subtle endocrinopathies that are prevalent in individuals presenting with the metabolic syndrome. Such derangements are of borderline character and often fall within the normal reference range. Intervention studies demonstrate that correction of relative hypogonadism in men with visceral obesity and other manifestations of the metabolic syndrome seem to decrease the abdominal fat mass and reverse the glucose intolerance, as well as lipoprotein abnormalities in the serum. Further analysis of the underlying mechanism has also disclosed a regulatory role for testosterone in counteracting visceral fat accumulation. Longitudinal epidemiological data demonstrates that relatively low testosterone levels are a risk factor for development of visceral obesity.</p><p>The primary event that triggers the initial development of visceral obesity is not known, but it seems plausible that increased activity in the hypothalamus-pituitary-adrenal axis can be of major importance.</p></div>","PeriodicalId":77027,"journal":{"name":"Bailliere's clinical endocrinology and metabolism","volume":"12 3","pages":"Pages 441-451"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-351X(98)80191-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21201387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 111

Dihydrotestosterone: A rationale for its use as a non-aromatizable androgen replacement therapeutic agent 双氢睾酮:其作为非芳香化雄激素替代治疗剂的基本原理

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80267-X

MD Ronald S. Swerdloff (Professor and Associate Chair, Department of Medicine, Chief, Division of Endocrinology), MD Christina Wang (Professor of Medicine, Director, General Clinical Research Center)

{"title":"Dihydrotestosterone: A rationale for its use as a non-aromatizable androgen replacement therapeutic agent","authors":"MD Ronald S. Swerdloff (Professor and Associate Chair, Department of Medicine, Chief, Division of Endocrinology), MD Christina Wang (Professor of Medicine, Director, General Clinical Research Center)","doi":"10.1016/S0950-351X(98)80267-X","DOIUrl":"10.1016/S0950-351X(98)80267-X","url":null,"abstract":"<div><p>Testosterone therapy is commonly used to treat male hypogonadism, androgen deficiency of severe illness, androgen deficiency of ageing and microphallus in infancy. The effects of testosterone are mediated directly as testosterone or after conversion to either dihydrotestosterone (DHT) or oestradiol. DHT is a potent androgen and cannot be aromatized to oestrogens, therefore acting as a pure androgen. DHT has been proposed as an androgen replacement therapy, with possible advantages over testosterone in certain circumstances in the ageing population as well as in patients with gynaecomastia and microphallus. A potential advantage of DHT over testosterone as an androgen replacement therapy is the reported and seemingly paradoxically muted effects of DHT on prostate growth. The decreased effect of DHT compared with testosterone on the prostate gland of humans may be due to the decrease in intraprostatic oestradiol levels. The potential beneficial effect of less prostate growth after DHT requires substantiation and, if true, must be balanced against any negative effects that might occur on bone, lipids and sexuality when a pure androgen replaces treatment with an aromatizable androgen.</p></div>","PeriodicalId":77027,"journal":{"name":"Bailliere's clinical endocrinology and metabolism","volume":"12 3","pages":"Pages 501-506"},"PeriodicalIF":0.0,"publicationDate":"1998-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-351X(98)80267-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21201391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 47

The use of testosterone as a male contraceptive 使用睾酮作为男性避孕药

Bailliere's clinical endocrinology and metabolism Pub Date : 1998-10-01 DOI: 10.1016/S0950-351X(98)80229-2

MD John K. Amory (Acting Instructor in Medicine), MD, PhD William J. Bremner (Professor and Vice-Chairman in Medicine Chief, Medical Service)

引用次数: 22